Tabalumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Lua error in Module:Infobox at line 166: malformed pattern (missing ']').

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.[1][2] Tabalumab was developed by Eli Lilly and Company.

A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.[3] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.[4]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx
  3. ↑ http://lilly.mediaroom.com/index.php?s=9042&item=136985
  4. ↑ http://www.genengnews.com/gen-news-highlights/lilly-halts-tabalumab-development-for-lupus/81250423/


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Now dropped by Lilly due to lack of efficacy.

Retrieved from "https://infogalactic.com/w/index.php?title=Tabalumab&oldid=707386637"